1. Switzerland Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Medartis Holding AG

Medartis Holding AG

83.41
CHF
+0.44
(+0.53%)
908.63MMarket Cap
Mar 02Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
7.01
7.88
8.95
11.42
11.08
10.85
13.55
15.45
17.33
18.16
21.69
- -
Basic EPS, GAAP
- -
0.62
0.28
0.07
0.4
0.18
-0.08
0.58
-0.49
0.05
0.29
0.67
- -
Free Cash Flow per Basic Share
- -
0.07
0.29
0.19
-0.76
-0.89
-0.04
0.9
-1.92
0.1
1.69
0.75
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-4.62
-4
1.46
1.45
18.59
18.35
18.09
18.96
20.05
20.63
21.75
22.19
22.65
Tangible Book Value per Share
-4.74
-4.11
1.34
0.74
17.8
17.29
17.12
17.95
14.15
15.4
17.57
2.77
2.85
Basic Weighted Avg Shares
12
12
12
12
11
12
12
12
12
12
12
12
12
Sales/Revenue/Turnover
- -
82
93
105
121
130
128
160
183
212
225
269
- -
Operating Margin (%)
- -
14.76
7.82
9.15
4.99
5.65
2.43
6.89
-1.02
3.92
3.21
0.72
- -
Depreciation Expense
- -
6
7
7
8
13
16
16
18
23
22
25
- -
Net Income, GAAP
- -
7
3
1
4
2
-1
7
-6
1
4
8
- -
Effective Tax Rate (%)
- -
4.99
37.34
89.23
- -
35.33
- -
17.51
- -
65.44
- -
27
- -
Profit Margin (%)
- -
8.83
3.58
0.82
3.46
1.65
-0.74
4.28
-3.16
0.29
1.57
3.1
- -
Working Capital
20
27
32
31
163
151
135
141
98
95
215
107
147
LT Debt
67
76
62
62
2
23
23
19
22
21
113
132
197
Total Equity
-54
-47
17
17
218
216
213
224
238
255
270
276
282
Return on Invested Capital (%)
- -
41.24
7.58
1.14
- -
2.04
- -
3.72
- -
0.98
- -
4.61
- -
Return on Capital (%)
- -
30.86
6.84
1.09
- -
1.17
- -
3.06
- -
0.33
- -
3.11
- -
Return on Common Equity (%)
- -
- -
- -
5.08
3.57
0.99
-0.44
3.13
-2.5
0.25
1.35
3.06
- -

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
8
26
11
LT Borrowings
- -
113
- -
LT Finance Leases
- -
19
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
12
12
12
Market Capitalization
825
1,139
909

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
265
195
209
Cash, Cash Equivalents & STI
121
33
26
Accounts Receivable, Net
46
50
58
Inventories
87
98
102
Total Current Liabilities
50
88
62
Payables & Accruals
- -
- -
- -
ST Debt
8
26
11
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
106.82%
5.32%
2.31%
Free Cash Flow
-147.45%
-244.91%
-55.47%
Net Income, GAAP
-44.96%
-102.67%
136.65%
Sales/Revenue/Turnover
12.82%
16.27%
19.76%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
225
2025
- -
- -
269
2026
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.29
2025
- -
- -
0.67
2026
- -
- -
- -

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Matthias Schupp
Full Time Employees
1,337
Sector
Health technology
Industry
Medical specialties
Address
Hochbergerstrasse 60E Basel BS Switzerland 4057
IPO Date
Mar 23, 2018
Website
medartis.com
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Medartis Holding AG, a Switzerland-based holding company of the Medartis Group founded in 1997 and headquartered in Basel, develops, manufactures and markets medical devices and implants for the surgical fixation of bone fractures and joint replacement in upper and lower extremities as well as the craniomaxillofacial region; its core product portfolio encompasses titanium screws and plates such as APTUS, Modus and SpeedTip systems, cannulated compression screws (CCS), intramedullary nails, Hand New Generation and Scaphoid plating solutions, Dorsal Olecranon plates, CMX personalized patient-specific implants and services, alongside the KeriMedical TOUCH prosthesis for thumb osteoarthritis; the company serves orthopedic, trauma and cranio-maxillofacial surgeons through subsidiaries in 13 locations including Warsaw (Indiana, USA), Umkirch (Germany) and direct sales in over 50 countries spanning EMEA, US, APAC and LATAM regions. Recent strategic developments include the full acquisition of KeriMedical in 2025 for CHF 99 million following FDA approval of its TOUCH prosthesis, enhancing joint replacement capabilities and surgeon networks in hand and wrist segments with added production in Archamps and Besançon, France; a majority 51% stake acquisition in NeoOrtho in Curitiba, Brazil announced with 2024 results for entry into the value segment of Latin American orthopedics with plans for full ownership by 2028/29 and a new modular facility by end-2025; US expansion via the Avenger Radial Head System from In2Bones Global in early 2025 to bolster elbow reconstruction; transition to direct sales in Japan expanding upper and lower extremities with sterile options and IBRA educational programs; in-sourcing of sterile packaging at Basel validated in 2024 targeting 70% internal production by spring 2025; and a CHF 115.8 million convertible bond issuance in April 2024 maturing 2031 to fund acquisitions alongside leadership changes including new CEO Matthias Schupp and US President David Thoni.